CAM
BCRX icon

Cresset Asset Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Cresset Asset Management’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$741K Sell
74,074
-740
-1% -$6.69K ﹤0.01% 1024
2026
Q1 		$712K Buy
+74,814
New +$581K ﹤0.01% 911

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Cresset Asset Management's BCRX Position: Q2 2026 in Review

Cresset Asset Management reduced its BioCryst Pharmaceuticals (BCRX) stake by 0.99% in Q2 2026, selling an estimated $6.69K and leaving 74,074 shares worth $741K. The position accounts for ﹤0.01% of the portfolio, ranked #1024.

Cresset Asset Management first reported a position in BCRX in Q1 2026 and has held it in 2 quarters since. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • Cresset Asset Management held 74,074 shares of BioCryst Pharmaceuticals worth $741K as of Q2 2026.
  • Cresset Asset Management sold 740 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $6.69K.
  • BioCryst Pharmaceuticals made up ﹤0.01% of Cresset Asset Management's portfolio in Q2 2026, its #1024 holding.
  • Cresset Asset Management first reported a position in BioCryst Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Cresset Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.